Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

414 results

Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
Horan JT, Haight A, Dioguardi JL, Brown C, Grizzle A, Shelman C, Kanter J, Hale G, Nieder M, Benton M, Kasow KA, Abraham A, Chiang KY. Horan JT, et al. Among authors: kanter j. Biol Blood Marrow Transplant. 2015 May;21(5):900-5. doi: 10.1016/j.bbmt.2015.01.015. Epub 2015 Jan 21. Biol Blood Marrow Transplant. 2015. PMID: 25617808 Free article. Clinical Trial.
Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke.
Dowling MM, Quinn CT, Ramaciotti C, Kanter J, Osunkwo I, Inusa B, Iyer R, Kwiatkowski JL, Johnson C, Rhodes M, Owen W, Strouse JJ, Panepinto JA, Neumayr L, Sarnaik S, Plumb PA, Dlamini N, Kirkham F, Hynan LS; PFAST Investigators. Dowling MM, et al. Among authors: kanter j. Br J Haematol. 2017 Jan;176(2):300-308. doi: 10.1111/bjh.14391. Epub 2016 Oct 21. Br J Haematol. 2017. PMID: 27766637 Free PMC article.
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. Among authors: kanter j. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.
Crizanlizumab in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J. Ataga KI, et al. Among authors: kanter j. N Engl J Med. 2017 May 4;376(18):1796. doi: 10.1056/NEJMc1703162. N Engl J Med. 2017. PMID: 28467874 No abstract available.
Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.
Kanter J, Heath LE, Knorr J, Agbenyega ET, Colombatti R, Dampier C, Hassab H, Manwani D, Robitaille N, Brown PB, Jakubowski JA, Yao S, Hoppe C. Kanter J, et al. Br J Haematol. 2019 Mar;184(6):1058-1061. doi: 10.1111/bjh.15250. Epub 2018 Apr 20. Br J Haematol. 2019. PMID: 29676449 Free article. No abstract available.
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. Niihara Y, et al. Among authors: kanter j. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. N Engl J Med. 2018. PMID: 30021096 Free article. Clinical Trial.
The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease.
DiMartino LD, Baumann AA, Hsu LL, Kanter J, Gordeuk VR, Glassberg J, Treadwell MJ, Melvin CL, Telfair J, Klesges LM, King A, Wun T, Shah N, Gibson RW, Hankins JS; Sickle Cell Disease Implementation Consortium. DiMartino LD, et al. Among authors: kanter j. Am J Hematol. 2018 Dec;93(12):E391-E395. doi: 10.1002/ajh.25282. Epub 2018 Oct 17. Am J Hematol. 2018. PMID: 30203558 Free PMC article. No abstract available.
Barriers to Pediatric Sickle Cell Disease Guideline Recommendations.
Cabana MD, Kanter J, Marsh AM, Treadwell MJ, Rowland M, Stemmler P, Bardach NS. Cabana MD, et al. Among authors: kanter j. Glob Pediatr Health. 2019 May 3;6:2333794X19847026. doi: 10.1177/2333794X19847026. eCollection 2019. Glob Pediatr Health. 2019. PMID: 31106244 Free PMC article.
Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease.
Brazauskas R, Scigliuolo GM, Wang HL, Cappelli B, Ruggeri A, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Panepinto JA, Rondelli D, Shenoy S, Walters MC, Wagner JE, Tisdale JF, Gluckman E, Eapen M. Brazauskas R, et al. Among authors: kanter j. Blood. 2020 Jul 30;136(5):623-626. doi: 10.1182/blood.2020005687. Blood. 2020. PMID: 32518950 Free PMC article.
Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry.
Glassberg JA, Linton EA, Burson K, Hendershot T, Telfair J, Kanter J, Gordeuk VR, King AA, Melvin CL, Shah N, Hankins JS, Epié AY, Richardson LD; Sickle Cell Disease Implementation Consortium. Glassberg JA, et al. Among authors: kanter j. Orphanet J Rare Dis. 2020 Jul 7;15(1):178. doi: 10.1186/s13023-020-01457-x. Orphanet J Rare Dis. 2020. PMID: 32635939 Free PMC article.
A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department.
Linton EA, Goodin DA, Hankins JS, Kanter J, Preiss L, Simon J, Souffront K, Tanabe P, Gibson R, Hsu LL, King A, Richardsona LD, Glassberg JA; Sickle Cell Disease Implementation Consortium. Linton EA, et al. Among authors: kanter j. Ann Emerg Med. 2020 Sep;76(3S):S64-S72. doi: 10.1016/j.annemergmed.2020.08.013. Ann Emerg Med. 2020. PMID: 32928465 Free PMC article.
Development of a Severity Classification System for Sickle Cell Disease.
Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Gordeuk VR, Kanter J, Klings ES, Lipato T, Manwani D, Scullin B, Yermilov I, Smith WR. Shah N, et al. Among authors: kanter j. Clinicoecon Outcomes Res. 2020 Oct 28;12:625-633. doi: 10.2147/CEOR.S276121. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 33149635 Free PMC article.
Kneeling Was the First Step for Sickle Cell Disease.
Desai P, Little J, Kanter J, Bridges K, Andemariam B, Lanzkron S. Desai P, et al. Among authors: kanter j. Ann Intern Med. 2021 Jul;174(7):1004-1005. doi: 10.7326/M20-7418. Epub 2021 Mar 23. Ann Intern Med. 2021. PMID: 33750189 No abstract available.
Gaps in the diagnosis and management of iron overload in sickle cell disease: a 'real-world' report from the GRNDaD registry.
Wilson SR, Sears M, Williams E, Drapekin J, Sivakumar I, Padrino S, Desai PC, Hager W, Manwani D, Clay LJ, Field JJ, Kanter J, Cohen AJ, Saif Ur Rehman S, Lanzkron S, Little JA; GRNDaD investigators. Wilson SR, et al. Among authors: kanter j. Br J Haematol. 2021 Dec;195(5):e157-e160. doi: 10.1111/bjh.17762. Epub 2021 Aug 22. Br J Haematol. 2021. PMID: 34423416 No abstract available.
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
Liles DK, Shah NR, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crary SE, Kraft WK, Archer N, Cataldo V, Hardesty BM, Idowu M, Desai PC, Ikeda A, Puthenveetil G, Hassell KL, Sarnaik S, Kutlar A. Liles DK, et al. Among authors: kanter j. Br J Haematol. 2021 Nov;195(4):e150-e153. doi: 10.1111/bjh.17739. Epub 2021 Oct 5. Br J Haematol. 2021. PMID: 34611900 No abstract available.
Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium.
Masese RV, Bulgin D, Knisely MR, Preiss L, Stevenson E, Hankins JS, Treadwell MJ, King AA, Gordeuk VR, Kanter J, Gibson R, Glassberg JA, Tanabe P, Shah N; Sickle Cell Disease Implementation Consortium. Masese RV, et al. Among authors: kanter j. PLoS One. 2021 Oct 29;16(10):e0258638. doi: 10.1371/journal.pone.0258638. eCollection 2021. PLoS One. 2021. PMID: 34714833 Free PMC article.
Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.
Smeltzer MP, Howell KE, Treadwell M, Preiss L, King AA, Glassberg JA, Tanabe P, Badawy SM, DiMartino L, Gibson R, Kanter J, Klesges LM, Hankins JS; Sickle Cell Disease Implementation Consortium. Smeltzer MP, et al. Among authors: kanter j. BMJ Open. 2021 Nov 17;11(11):e050880. doi: 10.1136/bmjopen-2021-050880. BMJ Open. 2021. PMID: 34789492 Free PMC article.
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Kwiatkowski JL, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Alshehri A, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Tricta F, Elalfy MS. Kwiatkowski JL, et al. Among authors: kanter j. Blood Adv. 2022 Feb 22;6(4):1243-1254. doi: 10.1182/bloodadvances.2021004938. Blood Adv. 2022. PMID: 34847228 Free PMC article. Clinical Trial.
Gene therapy for sickle cell disease: where we are now?
Kanter J, Falcon C. Kanter J, et al. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):174-180. doi: 10.1182/hematology.2021000250. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889358 Free PMC article.
GRNDaD: big data and sickle cell disease.
Lanzkron S, Manwani D, Desai P, Kanter J, Little J. Lanzkron S, et al. Among authors: kanter j. Blood Adv. 2022 Feb 8;6(3):1088. doi: 10.1182/bloodadvances.2021005282. Blood Adv. 2022. PMID: 35133406 Free PMC article.
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.
Kroner BL, Hankins JS, Pugh N, Kutlar A, King AA, Shah NR, Kanter J, Glassberg J, Treadwell M, Gordeuk VR; Sickle Cell Disease Implementation Consortium. Kroner BL, et al. Among authors: kanter j. Am J Hematol. 2022 May;97(5):603-612. doi: 10.1002/ajh.26495. Epub 2022 Feb 17. Am J Hematol. 2022. PMID: 35142007 Free PMC article.
Perspectives of individuals with sickle cell disease on barriers to care.
Phillips S, Chen Y, Masese R, Noisette L, Jordan K, Jacobs S, Hsu LL, Melvin CL, Treadwell M, Shah N, Tanabe P, Kanter J. Phillips S, et al. Among authors: kanter j. PLoS One. 2022 Mar 23;17(3):e0265342. doi: 10.1371/journal.pone.0265342. eCollection 2022. PLoS One. 2022. PMID: 35320302 Free PMC article.
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Åstrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR. Heeney MM, et al. Among authors: kanter j. Blood. 2022 Sep 29;140(13):1470-1481. doi: 10.1182/blood.2021014095. Blood. 2022. PMID: 35849650 Free PMC article. Clinical Trial.
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.
Dampier CD, Telen MJ, Wun T, Brown RC, Desai P, El Rassi F, Fuh B, Kanter J, Pastore Y, Rothman J, Taylor JG, Readett D, Sivamurthy KM, Tammara B, Tseng LJ, Lozier JN, Thackray H, Magnani JL, Hassell KL; RESET Investigators. Dampier CD, et al. Among authors: kanter j. Blood. 2023 Jan 12;141(2):168-179. doi: 10.1182/blood.2022015797. Blood. 2023. PMID: 35981565 Clinical Trial.
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center.
Hulbert ML, Manwani D, Meier ER, Alvarez OA, Brown RC, Callaghan MU, Campbell AD, Coates TD, Frei-Jones MJ, Hankins JS, Heeney MM, Hsu LL, Lebensburger JD, Quinn CT, Shah N, Smith-Whitley K, Thornburg C, Kanter J. Hulbert ML, et al. Among authors: kanter j. Pediatr Blood Cancer. 2023 Jan;70(1):e29961. doi: 10.1002/pbc.29961. Epub 2022 Sep 12. Pediatr Blood Cancer. 2023. PMID: 36094289
Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study.
Badawy SM, DiMartino L, Brambilla D, Klesges L, Baumann A, Burns E, DeMartino T, Jacobs S, Khan H, Nwosu C, Shah N, Hankins JS; Sickle Cell Disease Implementation Consortium. Badawy SM, et al. JMIR Form Res. 2022 Oct 14;6(10):e41415. doi: 10.2196/41415. JMIR Form Res. 2022. PMID: 36240004 Free PMC article.
What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease.
Lamont AE, Hsu LL, Jacobs S, Gibson R, Treadwell M, Chen Y, Lottenberg R, Axelrod K, Varughese T, Melvin C, Smith S, Chukwudozie IB, Kanter J; Sickle Cell Disease Implementation Consortium. Lamont AE, et al. Among authors: kanter j. PLoS One. 2022 Nov 11;17(11):e0272204. doi: 10.1371/journal.pone.0272204. eCollection 2022. PLoS One. 2022. PMID: 36367870 Free PMC article.
414 results